《大行報告》瑞信下調康哲藥業(00867.HK)目標價至12.9元 評級「中性」
瑞信發表報告表示,康哲藥業(00867.HK)上半年收入增15.7%至44.48億元人民幣,淨利潤按年增10.5%至17.99億元人民幣,收入及盈利均高於該行預期;公司上半年心腦血管及消化(CCV)業務銷量繼續呈良好增長,按年增26%,該行料今年CCV業務銷量可延續上半年上升趨勢,以及黛力新(Deanxit)藥品銷量於明年有更大的影響力。
該行表示,將公司今年至2024年各年每股盈測分別升12.6%、升4.2%及降3.6%,並將其目標價由13.1元下調至12.9元,維持其評級為「中性」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.